Replies to post #147352 on Biotech Values

[Robert C Jonson]

Whoever designed this ph2 trial in 2nd line NSCLC, whatever credential he had, even if he were God, his assumptions were incorrect, otherwise the trial would have met both primary and secondary endpoints.


jq1234, Bavi has been found to work more slowly than other drugs in trial, and I wonder if that would have any bearing on its stat. sig. performance? If the ORR, PFS, measurements and reporting were delayed longer after completion of enrollment, could that make a difference?
I know the company addressed this factor at the completion of their HCV trial.

[geocappy1]

Jq1234

I believe someone already pointed out that you may be confusing results of two different trials. The frontline study resulted in missed ORR and PFS endpoints. They are now awaiting MOS

The 2nd line trial had an ORR that was double the control group and the PFS was 40% and 50% better, respectively in the two Bavi dosed arms. They are awaiting the MOS data which also appears to be well outpacing the control group.